Keyphrases
T-AML
100%
Myelodysplasia
100%
Poor Prognosis
50%
Disease Risk
50%
Risk Factors
50%
Clinical Practice Guidelines
50%
Chemoresistance
50%
Therapy-related
50%
Disease Status
50%
Bone Marrow Transplantation
50%
Long Latency
50%
Short Latency
50%
Radiotherapy
50%
Chromosome 7
50%
Alkylating Agents
50%
Treatment Strategy
50%
Chromosomal Abnormalities
50%
Chemotherapy Regimen
50%
Latency Period
50%
Supportive Care
50%
Nonmyeloablative
50%
Myeloablative
50%
Prior Chemotherapy
50%
Cytotoxic Chemotherapy
50%
Curative Intent
50%
End-organ Damage
50%
Topoisomerase Inhibitors
50%
Prior Malignancy
50%
Low-dose Chemotherapy
50%
Medicine and Dentistry
Leukemia
100%
Myelodysplastic Syndrome
100%
Acute Myelogenous Leukemia
50%
Disease
16%
Cancer
16%
Drug Resistance
16%
Radiation Therapy
16%
Bone Marrow Transplantation
16%
Supportive Care
16%
Chemotherapy Regimens
16%
Chromosome 7
16%
Cytotoxic Chemotherapy
16%
Alkylating Antineoplastic Agent
16%
Low-Dose Chemotherapy
16%
End Organ Damage
16%
Chromosome Aberration
16%
Gyrase Inhibitor
16%
Chemotherapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Leukemia
100%
Myelodysplastic Syndrome
100%
Syndrome
33%
Chemotherapy
33%
Disease
16%
Drug Resistance
16%
Chromosome Aberration
16%
Alkylating Agent
16%
Chemotherapy Regimens
16%
Cytotoxic Chemotherapy
16%
Gyrase Inhibitor
16%